Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Definiens Ink High-Content Screening Technology Deal

NEW YORK, May 9 (GenomeWeb News) - Cenix BioScience and Definiens said today that they have signed a licensing and co-marketing agreement in the area of high-content screening.

 

Under the deal, Cenix will gain access to Definiens' Cellenger image analysis software system, integrating it into its high-throughput, high-content RNAi-based screening infrastructure. In exchange, Definiens will receive product development and marketing assistance from Cenix through beta-testing feedback, data sharing, and reference site support, the companies said.

 

Additional terms of the non-exclusive agreement were not disclosed.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.